Hanna, Catherine R.O’Cathail, Sean M.Graham, Janet S.Saunders, MarkSamuel, LeslieHarrison, MarkDevlin, LynseyEdwards, JoanneGaya, Daniel R.Kelly, Caroline A.Lewsley, Liz-AnneMaka, NooriMorrison, PaulaDinnett, LouiseDillon, SusanGourlay, JacquelinePlatt, Jonathan J.Thomson, FionaAdams, Richard A.Roxburgh, Campbell S. D.2021-09-162021-09-162021-08-26Hanna, C R, O’Cathail, S M, Graham, J S, Saunders, M, Samuel, L, Harrison, M, Devlin, L, Edwards, J, Gaya, D R, Kelly, C A, Lewsley, L-A, Maka, N, Morrison, P, Dinnett, L, Dillon, S, Gourlay, J, Platt, J J, Thomson, F, Adams, R A & Roxburgh, C S D 2021, 'Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer : a study protocol of a randomised phase II trial (PRIME-RT)', Radiation Oncology, vol. 16, no. 1, 163. https://doi.org/10.1186/s13014-021-01888-11748-717XRIS: urn:E6659C9791D353F3A3CEE3CD3A4F63D6RIS: Hanna2021ORCID: /0000-0002-8402-8670/work/100345921https://hdl.handle.net/2164/17086Acknowledgements We are grateful to Mr George Davidson and Ms Monica Jeffers for their input with writing the PRIME-RT protocol and patient information sheet. This study is co-sponsored by the University of Glasgow and NHS Greater Glasgow and Clyde. Funding PRIME-RT is funded by Astrazeneca and receives core funding from CRUK Clinical Trials Unit Glasgow for the purposes of trial set-up and data collection. The trial is co-sponsored by the University Of Glasgow and NHS Greater Glasgow and Clyde.9936077engSDG 3 - Good Health and Well-beingRectalneoplasmchemotherapyradiotherapyimmune-oncologyimmunotherapyclinical trialR MedicineCancer Research UKSupplementary InformationRJournal article10.1186/s13014-021-01888-1161